,4 Furthermore, adjuvant treatment with immune checkpoint blockade (or BRAF pathway targeted therapy in BRAF mutant melanoma patients) improved relapse-free survival (RFS) compared to placebo in phase 3 clinical trials5,6 and is now regarded as standard of care in high-risk stage III melanoma patients. The gene discussed is BRAF; the disease is melanoma.